What's in Juan J Badimon's pipeline?

Juan J Badimon has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Juan J Badimon's portfolio?

Top competitors by shared drug class: China National Center for Cardiovascular Diseases, Hospital Universitari Vall d'Hebron Research Institute.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/juan-j-badimon.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Juan J Badimon — Portfolio Competitive Intelligence Brief

Juan J Badimon pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Ticagrelor + ASA + Bivalirudin	Ticagrelor + ASA + Bivalirudin	marketed	Antiplatelet agent + anticoagulant combination	P2Y12 receptor, COX-1, thrombin	Cardiovascular
Clopidogrel + ASA + Bivalirudin	Clopidogrel + ASA + Bivalirudin	marketed	Antiplatelet agent + Anticoagulant combination	P2Y12 receptor, cyclooxygenase, thrombin	Cardiovascular

Therapeutic area mix

Cardiovascular · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

China National Center for Cardiovascular Diseases · 1 shared drug class
Hospital Universitari Vall d'Hebron Research Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Juan J Badimon:

Cite this brief

Drug Landscape (2026). Juan J Badimon — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/juan-j-badimon. Accessed 2026-05-16.